MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Revenue 2011-2026 | ONVO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 K | 109 K | 370 K | - | 2.2 M | 3.09 M | 4.6 M | 4.23 M | 1.48 M | 571 K | 379 K | 220 K | 1.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 M | 109 K | 1.55 M |
Quarterly Revenue Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 K | 28 K | 37 K | - | 24 K | 30 K | 39 K | - | 5 K | - | 75 K | - | 131 K | 77 K | 77 K | 1.5 M | - | - | - | - | - | - | - | - | 298 K | 298 K | 1.23 M | 668 K | 779 K | 779 K | 943 K | 1.1 M | 832 K | 946 K | 944 K | 812 K | 699 K | 2.4 M | 1.7 M | 891 K | 293 K | 689 K | 396 K | 306 K | 139 K | 139 K | - | 99 K | 135 K | 264 K | 129 K | - | 349 K | 1.08 M | 728 K | - | - | 232 K | 1.68 K | 1.68 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 1.68 K | 508 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Fulgent Genetics
FLGT
|
283 M | $ 15.48 | -5.49 % | $ 468 M |  USA |
|
Biodesix
BDSX
|
71.3 M | $ 13.64 | -6.58 % | $ 1.77 B | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 8.45 | - | $ 33.7 M |  Israel |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 477.84 | -2.25 % | $ 180 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 565.93 | -1.28 % | $ 45.5 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 118.67 | -4.61 % | $ 18.9 B | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.61 | -0.62 % | $ 61.9 M |  Irlanda |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 238.69 | -2.47 % | $ 25.5 B |  Schweiz |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
137 M | $ 17.21 | -0.86 % | $ 385 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 158.35 | -4.21 % | $ 7.85 B | USA |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Waters Corporation
WAT
|
932 M | $ 291.81 | -2.91 % | $ 17.4 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.75 | 3.38 % | $ 2.55 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 6.55 | -10.52 % | $ 388 M | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Exagen
XGN
|
66.6 M | $ 2.68 | -4.12 % | $ 57.8 M | USA |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.73 | 2.37 % | $ 7.59 M | USA |
 |
RadNet
RDNT
|
2.04 B | $ 56.85 | -4.31 % | $ 4.27 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.54 | -0.3 % | $ 273 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 266.88 | -0.56 % | $ 22.2 B | USA |
 |
VolitionRx Limited
VNRX
|
1.23 M | $ 0.2 | 0.03 % | $ 19.2 M |  Singapore |
 |
Psychemedics Corporation
PMD
|
22.1 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
15.2 M | $ 26.75 | -1.65 % | $ 34.7 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.11 | -2.06 % | $ 912 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.4 | 5.26 % | $ 92.3 M | USA |
 |
Quotient Limited
QTNT
|
43.4 M | - | -11.32 % | $ 1.1 M | Schweiz |